Table 4.
Author | Year | Age (Yr) | Sex | Comorbidities | Diagnosis | Positive Sample | Identification Technique | Antimicrobial Susceptibility | Treatment | Clinical Outcome |
---|---|---|---|---|---|---|---|---|---|---|
Jellinge et al75 | 2017 | 48 | Female | Subarachnoid haemorrhage | Unspecified | Tracheal culture | MALDI-TOF MS | S: Cefuroxime, gentamicin, ciprofloxacin R: Piperacillin/tazobactam |
None | Recovery |
Percutaneous dilatational tracheostomy | ||||||||||
Van Cleve et al27 | 2018 | 39 | Male | Motor vehicle versus pedestrian trauma | Ventilator-associated pneumonia | BAL | Not specified | S: Amikacin, aztreonam, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamycin, imipenem, piperacillin/tazobactam, tobramycin, trimethoprim/ sulfamethoxazole I: Ampicillin/sulbactam (LLL) R: Ampicillin/sulbactam (RLL), cefazolin |
Ceftazidime and vancomycin then piperacillin/tazobactam (total of 12 days) | Recovery |
50 | Male | MVC | Ventilator-associated pneumonia | BAL | Not specified | S: Amikacin, aztreonam, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, piperacillin/tazobactam, tobramycin, trimethoprim/ sulfamethoxazole R: Ampicillin/sulbactam (RLL), cefazolin |
Ampicillin/sulbactam then cefepime (total of 9 days) | Recovery | ||
Atrial fibrillation | ||||||||||
Myocardial infarction | ||||||||||
Pacemaker | ||||||||||
COPD | ||||||||||
Papakanderaki et al76 | 2018 | 75 | Male | NSCLC | Pulmonary infection | Sputum | Not specified | Not specified | Meropenem then ciprofloxacin | Recovery |
Left lower lobectomy | ||||||||||
Smoking (100 pack/years) |
Abbreviations: Yr, year; MVC, motor vehicle collision; COPD, chronic obstructive pulmonary disease; NSCLC, non-small cell lung cancer; BAL, bronchoalveolar lavage; MALDI-TOF MS, matrix assisted laser desorption ionization-time of flight mass spectrometry; S, susceptible; I, intermediate; R, resistant; LLL, left lower lobe; RLL, right lower lobe.